AE Wealth Management LLC Boosts Holdings in Catalent, Inc. (NYSE:CTLT)

AE Wealth Management LLC boosted its stake in Catalent, Inc. (NYSE:CTLT) by 22.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,304 shares of the company’s stock after acquiring an additional 7,502 shares during the period. AE Wealth Management LLC’s holdings in Catalent were worth $2,323,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of CTLT. Lindbrook Capital LLC raised its position in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent in the second quarter valued at about $42,000. Mather Group LLC. acquired a new stake in shares of Catalent during the first quarter worth about $52,000. Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the period.

Insider Activity at Catalent

In other Catalent news, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock valued at $782,923 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

CTLT has been the topic of several analyst reports. Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. StockNews.com assumed coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating on the stock. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Catalent has an average rating of “Hold” and an average target price of $58.08.

Catalent Stock Performance

NYSE:CTLT opened at $59.73 on Tuesday. The firm’s fifty day simple moving average is $59.52 and its 200-day simple moving average is $57.24. The company has a quick ratio of 1.77, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The stock has a market cap of $10.81 billion, a PE ratio of -9.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20.

Catalent (NYSE:CTLT) last issued its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Analysts expect that Catalent, Inc. will post 1.06 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.